Establishing Responder Definitions for Short-form Headache Impact Test (HIT-6) Total and Item Scores in Chronic Migraine

被引：0
|
作者：
Houts, Carrie R. [1 ]
Wirth, R. J. [1 ]
McGinley, James S. [1 ]
Lipton, Richard B. [2 ]
Hirman, Joe [3 ]
Cady, Roger [4 ]
机构：
[1] Vector Psychometr Grp LLC, Bronx, NY USA
[2] Albert Einstein Coll Med, Saul R Korey Dept Neurol, Bronx, NY USA
[3] Pacific Northwest Stat Consulting Inc, Woodinville, WA USA
[4] Alder BioPharmaceut Inc, Woodinville, WA USA
来源：
NEUROLOGY | 2020年 / 94卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
430
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Reductions in headache impact test (HIT-6) scores with fremanezumab and erenumab among patients with episodic migraine (EM) and 2-4 prior treatment failures: A network meta-analysis
    Pozo-Rosich, P.
    Patterson-Lomba, O.
    Mu, F.
    Thompson, S.
    Gandhi, S.
    Doctor, T.
    Bousleiman, S.
    Yang, R.
    Cohen, J. M.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [42] OnabotulinumtoxinA Treatment Reduces Adverse Impact of Chronic Migraine (CM): PREEMPT Clinical Program HIT-6 Results
    Lipton, R. B.
    Varon, S. F.
    Aurora, S. K.
    DeGryse, R. E.
    Turkel, C. C.
    HEADACHE, 2010, 50 : S47 - S48
  • [43] Reliability and validity of the 6-item Headache Impact Test in chronic migraine from the PROMISE-2 study
    Houts, Carrie R.
    McGinley, James S.
    Wirth, R. J.
    Cady, Roger
    Lipton, Richard B.
    QUALITY OF LIFE RESEARCH, 2021, 30 (03) : 931 - 943
  • [44] Headache-related disability measured with Headache impact test-6 (HIT-6) Results from an Estonian population-based survey
    Vaikjarv, M.
    Braschinsky, K.
    Raidvee, A.
    Braschinsky, M.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [45] Reliability and validity of the 6-item Headache Impact Test in chronic migraine from the PROMISE-2 study
    Carrie R. Houts
    James S. McGinley
    R. J. Wirth
    Roger Cady
    Richard B. Lipton
    Quality of Life Research, 2021, 30 : 931 - 943
  • [46] Onabotulinumtoxin-A treatment reduces adverse impact of chronic migraine (CM): PREEMPT clinical program HIT-6 results
    Lipton, R. B.
    Varon, S. F.
    Aurora, S. K.
    DeGryse, R. E.
    Turkel, C. C.
    JOURNAL OF HEADACHE AND PAIN, 2010, 11 : S11 - S11
  • [47] Network meta-analysis comparing atogepant vs. CGRP mAbs on headache impact test-6 total scores in episodic and chronic migraine
    Ailani, J.
    Dupont-Benjamin, L.
    Ashina, S.
    Takeshima, T.
    Lalla, A.
    Ubamadu, I.
    Pietri, G.
    Gandhi, P.
    Singh, R. B. Halker
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [48] Eptinezumab Demonstrated Early and Sustained Reductions in HIT-6 Total Score Over Time in Patients with Chronic Migraine in the PROMISE-2 Trial
    Lipton, R. B.
    McGinley, J. S.
    Houts, C.
    Wirth, R.
    Cady, R.
    HEADACHE, 2019, 59 : 159 - 160
  • [49] Early and Sustained Reduction in Headache Impact in People with CM After Eptinezumab Treatment: HIT-6 Item Analysis in the Phase 3 PROMISE-2 Trial
    McGinley, J. S.
    Buse, D.
    Wirth, R.
    Houts, C.
    Cady, R.
    Lipton, R. B.
    HEADACHE, 2019, 59 : 160 - 161
  • [50] Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 158 - 158
12345